# Psilocybin in Cancer Pain Study

> **NCT06001749** · PHASE2 · RECRUITING · sponsor: **Yvan Beaussant, MD, MSci** · enrollment: 15 (estimated)

## Conditions studied

- Opioid-Related Disorders
- Pain Management
- Pain Management and Care
- Advanced Cancer
- Advanced Cancers

## Interventions

- **DRUG:** Psilocybin

## Key facts

- **NCT ID:** NCT06001749
- **Lead sponsor:** Yvan Beaussant, MD, MSci
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-23
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-12-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06001749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06001749, "Psilocybin in Cancer Pain Study". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT06001749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*